Aktienanalyse zu Bio-Techne Corp (TECH)TECHBio-Techne Corp

Bio-Techne Corporation develop, manufacture and sell life science reagents, instruments and services for the research, diagnostics and bioprocessing markets worldwide. The Company’s segments include Protein Sciences segment and Diagnostics and Spatial Biology segment. The Protein Sciences segment is a developer and manufacturer of purified proteins and reagent solutions, most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. The Diagnostics and Spatial Biology segment develops and manufactures diagnostic products, including controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers. This segment also manufactures and sells fully automated multiomic spatial biology instrumentation and advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Bio-Techne Corp is not a strong buy at the current price of $72.57, as it is only slightly below the analyst price target of $73. The stock has shown a solid year-to-date change of +21.66%, but insider selling has increased by 174.32%, which raises concerns about future performance. Additionally, the forward P/E ratio is 34.60, indicating that the stock may be overvalued compared to its earnings potential.

9 analysts cover TECH: 6 rate it Buy, 3 Hold and 0 Sell. The average price target is 66.14.